KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Non Operating Income (2023 - 2025)

Fulgent Genetics (FLGT) has disclosed Non Operating Income for 3 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 99385.71% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 58.54% year-over-year, with the annual reading at $21.1 million for FY2025, 3655.97% up from the prior year.
  • Non Operating Income hit $7.0 million in Q4 2025 for Fulgent Genetics, down from $7.8 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.8 million in Q3 2025 to a low of -$15.2 million in Q4 2023.
  • Historically, Non Operating Income has averaged $1.3 million across 3 years, with a median of $310000.0 in 2024.
  • Biggest YoY gain for Non Operating Income was 99385.71% in 2025; the steepest drop was 123.48% in 2025.
  • Year by year, Non Operating Income stood at -$15.2 million in 2023, then soared by 100.05% to $7000.0 in 2024, then skyrocketed by 99385.71% to $7.0 million in 2025.
  • Business Quant data shows Non Operating Income for FLGT at $7.0 million in Q4 2025, $7.8 million in Q3 2025, and -$1.8 million in Q2 2025.